Pasar al contenido principal

RETVISION: Del diagnóstico genético molecular a las terapias avanzadas para tratar las enfermedades degenerativas de la retina

PI22/01747

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i en Salud
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON
Centro realización FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Topical Administration of Sitagliptin Prevents Retinal Neurodegeneration in a Model of Glaucoma Induced by Dexamethasone

  • Bogdanov, Patricia|||0000-0003-0669-4958
  • Duarri, Anna|||0000-0003-4075-5478
  • Sabater, David|||0000-0001-8113-8594
  • Canz, María José
  • Isla-Magrané, Helena|||0000-0002-7203-3309
  • Ramos, Hugo|||0000-0001-6443-7576
  • Deàs Just, Anna|||0000-0002-3129-6313
  • Simó Canonge, Rafael|||0000-0003-0475-3096
  • Hernández, Cristina|||0000-0002-3109-1721
Glaucoma is a neurodegenerative disease characterized by progressive degeneration of optic nerve axons and loss of retinal ganglion cells (RGCs). Although elevated intraocular pressure (IOP) is a major risk factor, many patients develop glaucoma with normal IOP, highlighting the need for neuroprotective therapies. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, has shown beneficial effects in diabetes-induced retinal neurodegeneration. This study aimed to evaluate whether sitagliptin eye drops, previously effective in diabetes-induced retinal neurodegeneration, could prevent corticosteroid-induced glaucoma. Glaucoma was induced in mice by periocular injection of dexamethasone (DEX) once weekly for five weeks. Sitagliptin or vehicle eye drops were administered from day 14 to 35. Untreated mice served as controls. DEX treatment caused significant loss of RGC bodies and optic nerve axons compared to controls, which was prevented by sitagliptin eye drops (p. < 0.001), without affecting IOP. Sitagliptin also inhibited DEX-induced activation of macroglia and microglia and prevented oligodendrocyte loss. Furthermore, it suppressed overexpression of galectin-3 and gamma-synuclein in the optic nerve head (ONH) (p < 0.001), key mediators of inflammation and apoptosis. Sitagliptin eye drops exert a potent neuroprotective effect against corticosteroid-induced glaucoma, supporting their potential as a novel therapeutic strategy for glaucoma.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Topical Administration of Sitagliptin Prevents Retinal Neurodegeneration in a Model of Glaucoma Induced by Dexamethasone

  • Sabater Martínez, David
  • Canz, María José
  • Bogdanov, Patricia
  • Duarri, Anna
  • Isla-Magrané, Helena
  • Ramos Abellán, Hugo
  • Deàs-Just, Anna
  • Simó Canonge, Rafael
  • Hernandez, Cristina
Dexamethasone-induced experimental model; Dipeptidyl peptidase 4 inhibitors; Eye drops, Modelo experimental inducido por dexametasona; Inhibidores de la dipeptidil peptidasa 4; Gotas oftálmicas, Model experimental induït per dexametasona; Inhibidors de la dipeptidil peptidasa 4; Gotes oftàlmiques, Glaucoma is a neurodegenerative disease characterized by progressive degeneration of optic nerve axons and loss of retinal ganglion cells (RGCs). Although elevated intraocular pressure (IOP) is a major risk factor, many patients develop glaucoma with normal IOP, highlighting the need for neuroprotective therapies. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, has shown beneficial effects in diabetes-induced retinal neurodegeneration. This study aimed to evaluate whether sitagliptin eye drops, previously effective in diabetes-induced retinal neurodegeneration, could prevent corticosteroid-induced glaucoma. Glaucoma was induced in mice by periocular injection of dexamethasone (DEX) once weekly for five weeks. Sitagliptin or vehicle eye drops were administered from day 14 to 35. Untreated mice served as controls. DEX treatment caused significant loss of RGC bodies and optic nerve axons compared to controls, which was prevented by sitagliptin eye drops (p < 0.001), without affecting IOP. Sitagliptin also inhibited DEX-induced activation of macroglia and microglia and prevented oligodendrocyte loss. Furthermore, it suppressed overexpression of galectin-3 and gamma-synuclein in the optic nerve head (ONH) (p < 0.001), key mediators of inflammation and apoptosis. Sitagliptin eye drops exert a potent neuroprotective effect against corticosteroid-induced glaucoma, supporting their potential as a novel therapeutic strategy for glaucoma., This research was funded by the “Ministerio de Industria, Economía y Competitividad” PDC2021-121638-I00, PID2022-138544OB-I00 and Instituto Carlos III-FEDER (RD21_0002_0052; PI22/01747). A.D-J. is a recipient of a grant from the “Ministerio de Industria, Economía y Competitividad” (PRE2020-095747). H.R is a recipient of the Torres Quevedo program funded by the Ministerio de Ciencia, Innovación y Universidades and the Agencia Estatal de Investigación (grant number PTQ2023-013246).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Diabetic retinopathy features in lund MetS rats

  • Canz, María José
  • Baguña-Torres, Julia
  • Huerta, Jordi
  • Isla-Magrané, Helena
  • Zufiaurre Seijo, Maddalen
  • Salas Torras, Anna
  • Simó Canonge, Rafael
  • Garcia-Arumi, Jose
  • Herance, Jose Raul
  • Bogdanov, Patricia
  • Duarri, Anna
  • Hernandez, Cristina
Diabetic retinopathy; Metabolic syndrome; Neurodegeneration, Retinopatía diabética; Síndrome metabólico; Neurodegeneración, Retinopatia diabètica; Síndrome metabòlica; Neurodegeneració, The Lund MetS rat (BBDR.cg-Leprdb/db.cp/LundRj) is a novel animal model that has a congenic leptin receptor deficiency (LepR−/−) and males exhibit a variety of metabolic abnormalities mimicking the human metabolic syndrome, including hyperglycemia, dyslipidemia, severe obesity, and a type 2 diabetes-like condition from 14 weeks of age. However, whether Lund MetS rats (LM rats) develop diabetic retinopathy is still unknown. The purpose is to investigate the features of diabetic retinopathy in this model. In this study, male LM rats aged 15 and 30 weeks were analyzed for pathological retinal changes, including vasculopathy, inflammation, reactive gliosis, oxidative stress, and neurodegeneration features on the retinas by histological, immunohistochemical, and gene and protein expression analysis. Compared with the non-diabetic LM rats, diabetic LM rats, mainly at 30 weeks of age, had a decrease in retinal thickness and loss of retinal ganglion cells and photoreceptors, indicating retinal neurodegeneration. They also presented an increase in VEGF-A expression, Endra, Icam-1, Vcam-1, and Endrb vascular genes, and albumin suggesting neurovascular unit dysfunction. Furthermore, retinas presented reactive gliosis and infiltration of microglia, TNF-α-positive vessels and expressed elevated levels of inflammatory genes Tnf-α, IL-18 and IL-6, and oxidative stress markers Sod2 and 8-hydroxy-2-deoxyguanosine (8-OHdG). Our results suggest that diabetic LM rats reproduce the early neurodegenerative and altered neuro-vascular features that also occur in the human diabetic eye., This research project was funded by grants from Instituto de Salud Carlos III (PI20/01588 and PI22/01747), Agència Gestió Ajuts Universitaris i de Recerca (2017SGR1303), and Ministerio de Ciencia e Innovación, Gobierno de España (PID2022-138544OB-100 and PID2021-122807OB-C32).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Clinical and Molecular Aspects of C2orf71/PCARE in Retinal Diseases

  • Zufiaurre Seijo, Maddalen
  • Garcia-Arumi, Jose
  • Duarri, Anna
Ciliopathies; Photoreceptors; Retina, Ciliopatías; Fotorreceptores; Retina, Ciliopaties; Fotoreceptors; Retina, Mutations in the photoreceptor-specific C2orf71 gene (also known as photoreceptor cilium actin regulator protein PCARE) cause autosomal recessive retinitis pigmentosa type 54 and cone-rod dystrophy. No treatments are available for patients with C2orf71 retinal ciliopathies exhibiting a severe clinical phenotype. Our understanding of the disease process and the role of PCARE in the healthy retina significantly limits our capacity to transfer recent technical developments into viable therapy choices. This study summarizes the current understanding of C2orf71-related retinal diseases, including their clinical manifestations and an unclear genotype-phenotype correlation. It discusses molecular and functional studies on the photoreceptor-specific ciliary PCARE, focusing on the photoreceptor cell and its ciliary axoneme. It is proposed that PCARE is an actin-associated protein that interacts with WASF3 to regulate the actin-driven expansion of the ciliary membrane during the development of a new outer segment disk in photoreceptor cells. This review also introduces various cellular and animal models used to model these diseases and provides an overview of potential treatments., This research project was funded by Instituto de Salud Carlos III, grant number PI22/01747.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Diabetic retinopathy features in lund MetS rats

  • Canz, María José
  • Baguña-Torres, Julia
  • Huerta, Jordi
  • Isla-Magrané, Helena
  • Zufiaurre Seijo, Maddalen
  • Salas Torras, Anna
  • Simó Canonge, Rafael
  • Garcia-Arumi, Jose
  • Herance, Jose Raul
  • Bogdanov, Patricia
  • Duarri, Anna
  • Hernandez, Cristina
Diabetic retinopathy; Metabolic syndrome; Neurodegeneration, Retinopatía diabética; Síndrome metabólico; Neurodegeneración, Retinopatia diabètica; Síndrome metabòlica; Neurodegeneració, The Lund MetS rat (BBDR.cg-Leprdb/db.cp/LundRj) is a novel animal model that has a congenic leptin receptor deficiency (LepR−/−) and males exhibit a variety of metabolic abnormalities mimicking the human metabolic syndrome, including hyperglycemia, dyslipidemia, severe obesity, and a type 2 diabetes-like condition from 14 weeks of age. However, whether Lund MetS rats (LM rats) develop diabetic retinopathy is still unknown. The purpose is to investigate the features of diabetic retinopathy in this model. In this study, male LM rats aged 15 and 30 weeks were analyzed for pathological retinal changes, including vasculopathy, inflammation, reactive gliosis, oxidative stress, and neurodegeneration features on the retinas by histological, immunohistochemical, and gene and protein expression analysis. Compared with the non-diabetic LM rats, diabetic LM rats, mainly at 30 weeks of age, had a decrease in retinal thickness and loss of retinal ganglion cells and photoreceptors, indicating retinal neurodegeneration. They also presented an increase in VEGF-A expression, Endra, Icam-1, Vcam-1, and Endrb vascular genes, and albumin suggesting neurovascular unit dysfunction. Furthermore, retinas presented reactive gliosis and infiltration of microglia, TNF-α-positive vessels and expressed elevated levels of inflammatory genes Tnf-α, IL-18 and IL-6, and oxidative stress markers Sod2 and 8-hydroxy-2-deoxyguanosine (8-OHdG). Our results suggest that diabetic LM rats reproduce the early neurodegenerative and altered neuro-vascular features that also occur in the human diabetic eye., This research project was funded by grants from Instituto de Salud Carlos III (PI20/01588 and PI22/01747), Agència Gestió Ajuts Universitaris i de Recerca (2017SGR1303), and Ministerio de Ciencia e Innovación, Gobierno de España (PID2022-138544OB-100 and PID2021-122807OB-C32).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Topical Administration of Sitagliptin Prevents Retinal Neurodegeneration in a Model of Glaucoma Induced by Dexamethasone

  • Sabater Martínez, David
  • Canz, María José
  • Bogdanov, Patricia
  • Duarri, Anna
  • Isla-Magrané, Helena
  • Ramos Abellán, Hugo
  • Deàs-Just, Anna
  • Simó Canonge, Rafael
  • Hernandez, Cristina
Dexamethasone-induced experimental model; Dipeptidyl peptidase 4 inhibitors; Eye drops, Modelo experimental inducido por dexametasona; Inhibidores de la dipeptidil peptidasa 4; Gotas oftálmicas, Model experimental induït per dexametasona; Inhibidors de la dipeptidil peptidasa 4; Gotes oftàlmiques, Glaucoma is a neurodegenerative disease characterized by progressive degeneration of optic nerve axons and loss of retinal ganglion cells (RGCs). Although elevated intraocular pressure (IOP) is a major risk factor, many patients develop glaucoma with normal IOP, highlighting the need for neuroprotective therapies. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, has shown beneficial effects in diabetes-induced retinal neurodegeneration. This study aimed to evaluate whether sitagliptin eye drops, previously effective in diabetes-induced retinal neurodegeneration, could prevent corticosteroid-induced glaucoma. Glaucoma was induced in mice by periocular injection of dexamethasone (DEX) once weekly for five weeks. Sitagliptin or vehicle eye drops were administered from day 14 to 35. Untreated mice served as controls. DEX treatment caused significant loss of RGC bodies and optic nerve axons compared to controls, which was prevented by sitagliptin eye drops (p < 0.001), without affecting IOP. Sitagliptin also inhibited DEX-induced activation of macroglia and microglia and prevented oligodendrocyte loss. Furthermore, it suppressed overexpression of galectin-3 and gamma-synuclein in the optic nerve head (ONH) (p < 0.001), key mediators of inflammation and apoptosis. Sitagliptin eye drops exert a potent neuroprotective effect against corticosteroid-induced glaucoma, supporting their potential as a novel therapeutic strategy for glaucoma., This research was funded by the “Ministerio de Industria, Economía y Competitividad” PDC2021-121638-I00, PID2022-138544OB-I00 and Instituto Carlos III-FEDER (RD21_0002_0052; PI22/01747). A.D-J. is a recipient of a grant from the “Ministerio de Industria, Economía y Competitividad” (PRE2020-095747). H.R is a recipient of the Torres Quevedo program funded by the Ministerio de Ciencia, Innovación y Universidades and the Agencia Estatal de Investigación (grant number PTQ2023-013246).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Clinical and Molecular Aspects of C2orf71/PCARE in Retinal Diseases

  • Zufiaurre Seijo, Maddalen
  • Garcia-Arumi, Jose
  • Duarri, Anna
Ciliopathies; Photoreceptors; Retina, Ciliopatías; Fotorreceptores; Retina, Ciliopaties; Fotoreceptors; Retina, Mutations in the photoreceptor-specific C2orf71 gene (also known as photoreceptor cilium actin regulator protein PCARE) cause autosomal recessive retinitis pigmentosa type 54 and cone-rod dystrophy. No treatments are available for patients with C2orf71 retinal ciliopathies exhibiting a severe clinical phenotype. Our understanding of the disease process and the role of PCARE in the healthy retina significantly limits our capacity to transfer recent technical developments into viable therapy choices. This study summarizes the current understanding of C2orf71-related retinal diseases, including their clinical manifestations and an unclear genotype-phenotype correlation. It discusses molecular and functional studies on the photoreceptor-specific ciliary PCARE, focusing on the photoreceptor cell and its ciliary axoneme. It is proposed that PCARE is an actin-associated protein that interacts with WASF3 to regulate the actin-driven expansion of the ciliary membrane during the development of a new outer segment disk in photoreceptor cells. This review also introduces various cellular and animal models used to model these diseases and provides an overview of potential treatments., This research project was funded by Instituto de Salud Carlos III, grant number PI22/01747.